NCT03874234View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics (PKs) Investigation of GSK3186899 in Healthy Subjects

PHASE1TerminatedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 30, 2019

Primary Completion Date

October 17, 2019

Study Completion Date

October 17, 2019

Conditions
Leishmaniasis
Interventions
DRUG

GSK3186899

GSK3186899 will be available as white to slightly colored, spray dried powder in a bottle to be administered orally along with mixture of propylene glycol and water.

DRUG

Placebo

Placebo will be available as white to slightly colored, blend powder in a bottle to be administered orally along with mixture of propylene glycol and water.

Trial Locations (1)

CB2 2GG

GSK Investigational Site, Cambridge

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY